ann out, page-2

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce that it has been included in the Standard & Poor's S&P/ASX 300 Index, effective from 19 September 2011.
Prima?s inclusion in the S&P/ASX 300 Index comes about as part of Standard & Poor's September quarterly review.
The S&P/ASX 300 Index is comprised principally of the 300 largest and most liquid stocks listed and traded on the Australian Stock Exchange. Inclusion in the S&P/ASX 300 Index is based on certain criteria regarding listing, size and liquidity, and Prima is delighted to have been included in the Index.
The S&P/ASX 300 provides up to an additional 100 small-cap stocks to the S&P/ASX 200, and is designed to address investment managers' needs to benchmark against a portfolio characterised by sufficient size and liquidity. The S&P/ASX 300 Index is a component of the Australian indices that can be utilised as building blocks for portfolio construction.
Prima is developing the CVac? ovarian cancer vaccine, and is currently undertaking late-stage clinical trials for the product. It is a therapy vaccine treatment designed to control the metastases of the cancer, delay the relapse of patients and extend patients? quality of life. The Company aims to commercialise CVac? into the multi-billion dollar global pharmacy oncology market.
Prima BioMed managing director Martin Rogers said: ?Standard & Poor's is the leading provider of market indices in Australia, and we are delighted to have been included in the S&P/ASX 300 for the first time. The inclusion in the Index is a strong validation of the Company?s continued growth, and it will assist in promoting our exposure within the Australian equity market."